Regeneron Sees Mixed Results on Gout Drug Trials - Wall Street Journal

Regeneron Sees Mixed Results on Gout Drug Trials Wall Street Journal Regeneron Pharmaceuticals Inc. reported Wednesday mixed results from Phase III trials of its gout drug Arcalyst, with one trial showing ... Regeneron gout drug works in one trial, fails otherReuters Regeneron's Billion Research Push Mimics GenentechBusinessWeek Ambitious Regeneron unveils mixed PhIII results for gout drugFierceBiotech Monthly Prescribing Reference -Motley Fool -PR Newswire (press release) all 74 news articles »

Clinical Trials Update: June 24, 2010 - BusinessWeek

Clinical Trials Update: June 24, 2010 BusinessWeek You may qualify for this study if you have had heart disease or blood circulation problems, are at least age 50 and have been diagnosed with gout. ...

Investigative Uricosuric Compound Lowers Serum Uric Acid in Patients With Gout ... - DG News

Investigative Uricosuric Compound Lowers Serum Uric Acid in Patients With Gout ... DG News "The results of this trial demonstrate that RDEA594 is a promising new drug for the treatment of hyperuricaemia in gout patients and support the initiation ... Study Confirms Febuxostat Utility in Reducing Serum Uric Acid to Goal Among ...DG News EULAR: Meta-Analysis Confirms Febuxostat Utility in Gout PatientsMedPage Today all 3 news articles »

EULAR: New Gout Fighters in Development - MedPage Today

EULAR: New Gout Fighters in Development MedPage Today Among the new compounds is Ardea Biosciences' RDEA594, now moving into phase III clinical trials, and several other compounds that show potential so far ... EULAR: Experimental Compound Helps Gout Patients, Lowers Uric AcidMedPage Today EULAR: Canakinumab Prevents Flares in Gout PatientsMedPage Today EULAR: Febuxostat Bests Allopurinol in GoutMedPage Today all 8 news articles »